Co-Operative Multicenter Trials in Obstetrics & Maternal Fetal Medicine

描述（由申请人提供）：本申请的目的是为韦恩州立大学（WSU）继续作为母胎医学单位（MFMU）网络站点。关于MFMU网络的学术生产力，WSU在患者招募和保留/完成方面排名中等，在依从性/数据质量方面排名5.5，在TSH试验中有100%的12个月和24个月婴儿随访。在当前资助周期启动的2项随机对照试验中，14个MFMU中心招募的非裔美国患者中，WSU贡献了不成比例的高数量（21%）。WSU首席研究员参加了委员会和小组委员会，并为TSH方案的研究开发和设计做出了贡献。华盛顿州立大学的研究人员提交了10份提案，并首次发表了6篇MFMU出版物。WSU MFMU团队通过在研究设计、多中心随机临床试验、经验丰富的研究人员以及广泛的研究基础设施方面具有知识和经验的高素质领导实现了目标。WSU首席研究员将他的保护时间增加到50%，致力于MFMU相关活动，并正在增加2个站点，这将使WSU用于MFMU招募的患者人数增加70%，达到9418次/年。这三个地点的卫生保健提供者必须为所有患者提供筛查和纳入研究的机会。母胎工作人员，包括13名教师和7名研究员，非常富有成效，发表了265篇同行评审论文，并为11项合作或多中心设计的非mfmu研究做出了贡献。自1986年以来，华盛顿州立大学一直是NICHD新生儿研究网络的中心。大型高质量围产期数据系统协助编写本应用程序，并具有独特的MFMU研究护士MFMU入组患者通知系统。特殊优势包括具有研究管理经验的教师，莫特研究中心和NICHD围产期研究分部。我们的概念建议的中心假设是，阿奇霉素治疗将降低自发性早产（SPTB）的风险，妇女（Uu）进行中期遗传羊膜穿刺术临床指征，并通过聚合酶链反应（PCR）在羊水中检测解脲原体。该概念提案是一项随机、双盲、安慰剂对照、多中心试验。提议的研究具有创新性。结果可能会改变实践，为羊膜穿刺术中获得的房颤的常规PCR检测提供坚实的基础，用于临床适应症、抗生素的使用和减少PTB。这项研究计划有望减少肺结核，改善孕妇及其新生儿的健康。

DESCRIPTION (provided by applicant): The objective of this application is for Wayne State University (WSU) to continue as a Maternal-Fetal Medicine Unit (MFMU) network site. With respect to academic productivity in the MFMU network WSU is ranked in the middle for patient recruitment and retention/completion, and 5.5 in adherence/data quality, with 100% 12 and 24 months infant follow-up in the TSH trial. WSU contributed a disproportionately high number (21%) of African American patients enrolled, by the 14 MFMU centers, to the 2 RCTs initiated in the current funding cycle. The WSU Principal Investigator participated in Committees and Subcommittees, and contributed to research development and design of the TSH protocol. WSU investigators submitted 10 proposals and first authored 6 MFMU publications. The WSU MFMU team achieved the objectives with highly qualified leadership that has knowledge and experience in research design, and collaboration in multicenter randomized clinical trials, experienced research staff, in the presence of extensive research infrastructure. The WSU Principal Investigator increased his protected time to 50%, dedicated to MFMU related activities, and is adding 2 sites, which will increase the patient population available at WSU for MFMU recruitment by 70% to 9418 deliveries/year. Health care providers in the 3 sites are required to provide access to all patients for screening and enrollment to research studies. Maternal-fetal staff, including 13 faculty and 7 fellows, are very productive with 265 peer-reviewed publications, and contribution to 11 non-MFMU studies of cooperative or multicenter design. WSU has been a center in the NICHD Neonatal Research Network since 1986. The large high quality perinatal data system assisted in writing this application, and has a unique notification system for MFMU research nurses of MFMU enrolled patients. Special strengths include faculty with experience in research administration, the Mott center for research, and the NICHD Perinatology Research Branch. The central hypothesis of our concept proposal is that treatment with azithromycin will reduce the risk of spontaneous preterm birth (SPTB) among women that (Uu) undergo mid-trimester genetic amniocentesis for clinical indications, and have Ureaplasma urealyticum detected in amniotic fluid, by polymerase chain reaction (PCR). The concept proposal is a randomized, double-blind, placebo controlled, multicenter trial. The proposed research is innovative. Results could change practice, by providing a strong foundation for routine PCR testing of AF obtained during amniocentesis for clinical indications, administration of antibiotics, and reduction in PTB. The research proposal is expected to reduce PTB and improve the health of pregnant women their neonates.